MediciNova, Inc. (MNOV)
NASDAQ: MNOV · Real-Time Price · USD
1.750
+0.005 (0.29%)
Oct 30, 2024, 4:00 PM EDT - Market closed
MediciNova Revenue
MediciNova had revenue of $1.00M in the twelve months ending June 30, 2024. In the year 2023, MediciNova had annual revenue of $1.00M.
Revenue (ttm)
$1.00M
Revenue Growth
n/a
P/S Ratio
85.83
Revenue / Employee
$76,923
Employees
13
Market Cap
85.83M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CytomX Therapeutics | 119.57M |
InterCure | 72.42M |
Clearside Biomedical | 7.52M |
Vistagen Therapeutics | 971.00K |
Monogram Technologies | 365.00K |
Zentek | 25.80K |
MNOV News
- 7 days ago - MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium) - GlobeNewsWire
- 4 weeks ago - MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) - GlobeNewsWire
- 7 weeks ago - MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND - GlobeNewsWire
- 2 months ago - MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting - GlobeNewsWire
- 2 months ago - MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition - GlobeNewsWire
- 4 months ago - MediciNova Chief Business Officer David H. Crean, Ph.D. - GlobeNewsWire
- 5 months ago - MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer - GlobeNewsWire
- 5 months ago - MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 - GlobeNewsWire